100+ Free Arab Board Oncology Part 1 Practice Questions

Prepare for the Arab Board Medical Oncology Primary (Part 1) Written Examination - الامتحان الأولي لاختصاص طب الأورام (ABHS) exam with instant access — no signup required.

✓ No registration✓ No credit card✓ No hidden fees✓ Start practicing immediately

100+ Questions

100% Free

Loading practice questions...

Same family resources

Explore More Arab Board Specialty Certification Exams

Continue into nearby exams from the same family. Each card keeps practice questions, study guides, flashcards, videos, and articles in one place.

Sample Arab Board Oncology Part 1 Practice Questions

Try these sample questions to test your Arab Board Oncology Part 1 exam readiness. Each question includes a detailed explanation. Start the interactive quiz above for the full 100+ question experience with AI tutoring.

1Which cyclin-dependent kinase (CDK) complex is primarily responsible for phosphorylating the retinoblastoma protein (pRb) to drive the cell cycle transition from G1 into S phase?

A.Cyclin B - CDK1

B.Cyclin D - CDK4/6

C.Cyclin A - CDK2

D.Cyclin B - CDK2

Explanation: The Cyclin D-CDK4/6 complex mediates the initial mono- and hypo-phosphorylation of the retinoblastoma protein (pRb) during early-to-mid G1 phase. This relieves transcriptional repression and allows Cyclin E-CDK2 to hyperphosphorylate pRb, releasing E2F transcription factors to drive expression of genes necessary for S-phase entry. CDK1 complexes (such as Cyclin B-CDK1) regulate the G2/M transition rather than the G1/S transition.

2In the intrinsic (mitochondrial) apoptosis pathway, which event directly triggers the assembly of the apoptosome in the cytosol?

A.Binding of Fas ligand to the Fas death receptor

B.Translocation of Bid to the plasma membrane

C.Release of cytochrome c from mitochondria and its binding to Apaf-1

D.Direct cleavage of Caspase-3 by active Caspase-8

Explanation: Intrinsic apoptosis is initiated by cellular stress that causes mitochondrial outer membrane permeabilization (MOMP) via BAX/BAK pore formation. This releases cytochrome c into the cytoplasm, where it binds to apoptotic protease activating factor-1 (Apaf-1) in the presence of dATP/ATP to form the heptameric apoptosome. The apoptosome then recruits and activates procaspase-9, which subsequently cleaves and activates downstream executioner caspases like Caspase-3 and Caspase-7.

3Which adaptor protein is directly recruited to death receptors (such as Fas/CD95 and TRAIL-R1/R2) to form the Death-Inducing Signaling Complex (DISC) during extrinsic apoptosis?

A.FADD (Fas-Associated Death Domain)

B.Apaf-1

C.TRADD acting as an inhibitor of caspase activation

D.SMAC/DIABLO

Explanation: Upon binding of cognate ligands to death receptors, receptor trimerization clusters intracellular death domains, which recruit FADD via homotypic death domain interactions. FADD contains a death effector domain (DED) that recruits procaspase-8 or procaspase-10 to assemble the DISC, enabling dimerization and auto-activation of initiator caspases. Apaf-1 is specific to the intrinsic pathway, while SMAC/DIABLO acts by neutralizing inhibitors of apoptosis proteins (IAPs).

4What is the primary mechanism by which approximately 85% to 90% of human malignant tumors maintain telomere length to achieve replicative immortality?

A.Alternative lengthening of telomeres (ALT) via homologous recombination

B.Reactivation or transcriptional upregulation of telomerase reverse transcriptase (TERT)

C.Constitutive activation of shelterin complex degradation

D.Hypermethylation of the entire telomeric TTAGGG hexamer repeat array

Explanation: Most human cancers bypass the Hayflick limit and cellular senescence by reactivating telomerase, a ribonucleoprotein enzyme composed of the catalytic subunit TERT and the RNA template TERC. TERT promoter mutations (e.g., C228T and C250T), promoter hypermethylation, gene amplification, or transcriptional activation by MYC are common mechanisms. The alternative lengthening of telomeres (ALT) pathway is utilized by only 10% to 15% of tumors, most frequently sarcomas and CNS neoplasms.

5Under normoxic cellular conditions, how is the alpha subunit of hypoxia-inducible factor 1 (HIF-1alpha) targeted for rapid proteasomal degradation?

A.Hydroxylation of specific proline residues by prolyl hydroxylase domain (PHD) proteins, facilitating binding to pVHL

B.Phosphorylation by glycogen synthase kinase 3 beta (GSK3beta), causing MDM2-mediated ubiquitination

C.Direct sumoylation by SENP1, preventing nuclear export

D.Cleavage by caspase-3 upon release from the inner mitochondrial membrane

Explanation: In the presence of oxygen, prolyl hydroxylases (PHD1-3) utilize molecular O2 and 2-oxoglutarate to hydroxylate two conserved proline residues (Pro402 and Pro564) on HIF-1alpha. Hydroxylated HIF-1alpha is recognized with high affinity by the von Hippel-Lindau tumor suppressor protein (pVHL), an E3 ubiquitin ligase recognition component, leading to polyubiquitination and 26S proteasomal degradation. In hypoxia, PHD activity is inhibited, allowing HIF-1alpha to stabilize, translocate to the nucleus, heterodimerize with HIF-1beta, and drive transcription of VEGF, GLUT1, and EPO.

6The Warburg effect in cancer cells is best characterized by which metabolic alteration?

A.Exclusive reliance on beta-oxidation of fatty acids in the absence of glucose

B.Increased rate of glycolysis and conversion of pyruvate to lactate even in the presence of abundant oxygen

C.Complete cessation of ATP generation by substrate-level phosphorylation

D.Shift of glucose flux entirely into the urea cycle to eliminate excess nitrogen

Explanation: The Warburg effect (aerobic glycolysis) is a hallmark of cancer metabolism where malignant cells preferentially convert glucose to lactate via glycolysis even when oxygen is fully available for oxidative phosphorylation. Although glycolysis generates fewer ATP molecules per glucose molecule than oxidative phosphorylation, it operates at a vastly higher rate and diverts glycolytic intermediates into biosynthetic pathways (e.g., the pentose phosphate pathway and one-carbon metabolism) to support rapid cell growth and biomass generation.

7During epithelial-to-mesenchymal transition (EMT), which molecular change is considered the prototypical hallmark of lost epithelial polarity and gained motility?

A.Downregulation of E-cadherin with concomitant upregulation of N-cadherin and vimentin

B.Upregulation of E-cadherin and loss of Snail/Slug transcription factors

C.Repression of matrix metalloproteinases (MMPs) and increased claudin expression

D.Downregulation of integrin-linked kinase and loss of fibronectin deposition

Explanation: The hallmark of EMT is the 'cadherin switch', characterized by the loss of membrane E-cadherin (CDH1) mediated by transcriptional repressors such as Snail, Slug, Twist, and ZEB1/2. As epithelial adherens junctions disassemble, cells upregulate mesenchymal markers including N-cadherin, vimentin, and fibronectin, facilitating invasion and resistance to anoikis.

8In the canonical Wnt/beta-catenin signaling pathway, what occurs in the cytoplasm when Wnt ligands bind to Frizzled receptors and LRP5/6 coreceptors?

A.The beta-catenin destruction complex is activated, phosphorylating beta-catenin for ubiquitination

B.Dishevelled (Dvl) is recruited, leading to inhibition of the destruction complex and accumulation of unphosphorylated beta-catenin

C.GSK3beta is phosphorylated and directly translocates to the nucleus to repress TCF/LEF

D.Beta-catenin is cleaved by caspase-8 into active transcriptional fragments

Explanation: When Wnt ligands bind Frizzled and LRP5/6, Dishevelled (Dvl) is recruited and phosphorylated, which recruits and disrupts the Axin/APC/GSK3beta/CK1 destruction complex. Consequently, beta-catenin is not phosphorylated at serine/threonine residues, escaping beta-TrCP-mediated ubiquitination and proteasomal degradation. Accumulated beta-catenin translocates to the nucleus, associates with TCF/LEF transcription factors, and activates target genes such as CCND1 (Cyclin D1) and MYC.

9Which enzymatic complex performs the critical intramembrane proteolytic cleavage (S3 cleavage) of the Notch receptor to release the Notch intracellular domain (NICD)?

A.ADAM10 / ADAM17 metalloprotease

B.Gamma-secretase complex (containing Presenilin 1/2)

C.Caspase-9

D.Granzyme B

Explanation: Notch receptor activation occurs through a sequential two-step proteolytic cascade upon binding Delta-like or Jagged ligands. The S2 cleavage is performed extracellularly by ADAM family metalloproteases, followed by the S3 intramembrane cleavage executed by the gamma-secretase complex (composed of Presenilin, Nicastrin, APH-1, and PEN-2). This S3 cleavage liberates the Notch intracellular domain (NICD), which translocates to the nucleus and binds CSL/RBP-Jk to activate target gene transcription (e.g., HES1 and HEY1).

10In the canonical Hedgehog signaling pathway, what is the biochemical role of the 12-transmembrane receptor Patched-1 (PTCH1) in the absence of Sonic Hedgehog ligand?

A.It constitutively inhibits the 7-transmembrane transducer Smoothened (SMO)

B.It directly phosphorylates GLI1 to stimulate nuclear translocation

C.It binds to SUFU to induce degradation of GLI3

D.It activates adenylate cyclase to produce cyclic GMP

Explanation: In the 'off' state (absence of Hedgehog ligand), the receptor Patched-1 (PTCH1) constitutively represses the downstream transmembrane protein Smoothened (SMO), preventing its accumulation in primary cilia. When Sonic Hedgehog (SHH) binds PTCH1, this inhibition is relieved, allowing SMO to activate and prevent proteolytic processing of GLI transcription factors into repressors, thereby driving transcription of Hedgehog target genes (e.g., GLI1, PTCH1, CCND1).

About the Arab Board Oncology Part 1 Exam

The Arab Board Oncology Part 1 Written Examination is the initial milestone examination for oncology residents across the Arab world under the Arab Board of Health Specializations (ABHS). It evaluates candidates on the essential scientific foundation of oncology, including molecular cancer biology, oncogenes and tumor suppressor genes, hereditary cancer syndromes, clinical radiobiology and radiation physics, cancer pharmacology (conventional cytotoxic chemotherapy, targeted therapy, and immunotherapy), cancer epidemiology, and diagnostic tumor pathology.

Assessment

A single written paper of single-best-answer multiple-choice questions focusing on fundamental cancer sciences, pharmacology, radiobiology, and pathology.

Time Limit

Approximately 2.5 to 3 hours

Passing Score

The passing standard is established by the ABHS Scientific Council of Oncology, generally benchmarked at approximately 60%.

Exam Fee

Set by the Arab Board of Health Specializations and member country local accreditation offices. (Arab Board of Health Specializations (ABHS) - Scientific Council of Oncology)

Arab Board Oncology Part 1 Exam Content Outline

15%

Cancer Biology & Molecular Pathways

Hallmarks of cancer, cell cycle checkpoints, apoptosis, angiogenesis, and intracellular signaling.

15%

Oncogenes & Tumor Suppressor Genes

Tumor suppressor gene inactivation, oncogene activation, RAS/MAPK, PI3K/AKT/mTOR, and TP53/RB pathways.

12%

Cancer Genetics & Hereditary Syndromes

Hereditary cancer syndromes, DNA mismatch repair, homologous recombination deficiency, and genetic counseling concepts.

12%

Radiobiology & Radiation Physics

The 5 Rs of radiobiology, linear energy transfer, cell survival curves, fractionation, and radiation toxicity.

16%

Cancer Pharmacology - Cytotoxic Chemotherapy

Mechanisms, toxicities, metabolism, and resistance profiles of classic antineoplastic chemotherapy agents.

16%

Cancer Pharmacology - Targeted Therapy & Immunotherapy

Tyrosine kinase inhibitors, immune checkpoint blockade, antibody-drug conjugates, CAR-T therapy, and irAEs.

Cancer Epidemiology & Carcinogenesis

Viral, chemical, and physical carcinogens, epidemiology of common malignancies, and clinical trial methodology.

Tumor Pathology & Diagnostic Biomarkers

Diagnostic immunohistochemistry, molecular testing (NGS, FISH, PCR), TNM staging concepts, and prognostic markers.

How to Pass the Arab Board Oncology Part 1 Exam

What You Need to Know

Passing score: The passing standard is established by the ABHS Scientific Council of Oncology, generally benchmarked at approximately 60%.
Assessment: A single written paper of single-best-answer multiple-choice questions focusing on fundamental cancer sciences, pharmacology, radiobiology, and pathology.
Time limit: Approximately 2.5 to 3 hours
Exam fee: Set by the Arab Board of Health Specializations and member country local accreditation offices.

Keys to Passing

Work through all 100 available questions
Review every answer and explanation
Track weak areas and revisit them
Use our AI tutor for tough concepts

Arab Board Oncology Part 1 Study Tips from Top Performers

1Focus heavily on the mechanism of action, key organ toxicities, and primary resistance pathways of major cytotoxic and targeted oncology drugs, as pharmacology represents a substantial portion of the exam.

2Master the classic 5 Rs of radiobiology (Repair, Reassortment, Repopulation, Reoxygenation, and Radiosensitivity) and linear-quadratic model survival curves.

3Understand the molecular pathways of hereditary cancer syndromes (such as Lynch syndrome, Li-Fraumeni, and BRCA1/2-associated HBOC) and the cellular DNA damage response mechanisms.

Frequently Asked Questions

What is the scope and eligibility for the Arab Board Oncology Part 1 Exam?

The Part 1 examination is typically taken by oncology trainees after completing their initial basic science and core clinical residency rotations in an ABHS-accredited training hospital. It tests foundational knowledge in basic cancer biology, genetics, pharmacology, radiobiology, and pathology before clinical subspecialty progression.

What is the format and duration of the Part 1 written exam?

The examination comprises 100 single-best-answer multiple choice questions (MCQs) with four options each, administered in a single paper over a duration of 2.5 to 3 hours.

What is the passing score for the Arab Board Oncology Part 1 exam?

While the exact cut score is determined using psychometric standard-setting by the ABHS Scientific Council of Oncology, the traditional passing mark is approximately 60%.

Which reference textbooks are recommended for Arab Board Oncology Part 1 preparation?

Recommended reference sources include DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology, The Basic Science of Oncology by Tannock and Hill, Radiobiology for the Radiologist by Eric Hall, and Goodman & Gilman's The Pharmacological Basis of Therapeutics (Oncology sections).

100+ Free Arab Board Oncology Part 1 Practice Questions

Explore More Arab Board Specialty Certification Exams

Arab Board Pediatrics Part 1 Written Exam (ABHS)

Arab Board Anatomic Pathology Part 1 Written Exam (ABHS)

Arab Board Anesthesia and Intensive Care Final Clinical and Oral Exam (ABHS)

Arab Board Anesthesia and Intensive Care Final Written Exam (ABHS)

Arab Board Anesthesia Part 1 Written Exam (ABHS)

Arab Board Clinical Pathology Part 1 Written Exam (ABHS)